SCHEMBL31433299

SCHEMBL31433299

CSCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 1/20 0.49
▸ MAPK9 P45984 1/20 0.49
▸ MAPK10 P53779 1/20 0.49
▸ NPY5R Q15761 5/20 0.49
▸ NPY4R P50391 5/20 0.49
▸ NPY1R P25929 4/20 0.49
▸ IL23R Q5VWK5 1/20 0.49
▸ GLP1R P43220 1/20 0.47
▸ GCGR P47871 1/20 0.47
▸ GIPR P48546 1/20 0.47
▸ NPY2R P49146 2/20 0.47
▸ FNTA P49354 3/20 0.47
▸ FNTB P49356 3/20 0.47
▸ PGGT1B P53609 3/20 0.47
▸ BACE1 P56817 4/20 0.46
▸ BACE2 Q9Y5Z0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31433291 0.93 NPY4R (0.42) MAPK8MAPK9MAPK10NPY5RNPY4R
SCHEMBL31433321 0.91 NPY4R (0.42) MAPK8MAPK9MAPK10NPY5RNPY4R
SCHEMBL30262032 0.88 NPY4R (0.56) NPY5RNPY4RNPY1RIL23RGLP1R
SCHEMBL31433293 0.87 MAPK8 (0.58) MAPK8MAPK9MAPK10NPY5RNPY4R
SCHEMBL29883741 0.87 IL23R (0.46) MAPK8MAPK9MAPK10NPY5RNPY4R
SCHEMBL31433369 0.86 APLNR (0.59) MAPK8MAPK9MAPK10
SCHEMBL30272463 0.86 IL23R (0.51) NPY5RNPY4RNPY1RIL23RNPY2R
SCHEMBL31433236 0.86 MAPK8 (0.58) MAPK8MAPK9MAPK10NPY5RNPY4R
SCHEMBL26886947 0.86 GLP1R (0.44) NPY5RNPY4RNPY1RIL23RGLP1R
SCHEMBL30648493 0.85 GLP1R (0.58) NPY5RNPY4RNPY1RIL23RGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E CALICO LIFE SCIENCES LLC (US) 2025-03-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E MICA, CD74, HLA-DRB1 MAPK8 4358/4885MAPK9 3139/4885MAPK10 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback